Advertisement
U.S. markets close in 4 hours 26 minutes
  • S&P 500

    5,254.75
    +6.26 (+0.12%)
     
  • Dow 30

    39,775.57
    +15.49 (+0.04%)
     
  • Nasdaq

    16,406.60
    +7.08 (+0.04%)
     
  • Russell 2000

    2,127.18
    +12.83 (+0.61%)
     
  • Crude Oil

    82.59
    +1.24 (+1.52%)
     
  • Gold

    2,236.40
    +23.70 (+1.07%)
     
  • Silver

    25.00
    +0.25 (+1.00%)
     
  • EUR/USD

    1.0805
    -0.0025 (-0.23%)
     
  • 10-Yr Bond

    4.1910
    -0.0050 (-0.12%)
     
  • GBP/USD

    1.2637
    -0.0001 (-0.01%)
     
  • USD/JPY

    151.1970
    -0.0490 (-0.03%)
     
  • Bitcoin USD

    71,187.34
    +2,169.88 (+3.14%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,969.96
    +37.98 (+0.48%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Barclays 2021 Global Healthcare Conference on Thursday, March 11, 2021 at 2:25 p.m. ET.

The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit www.beamtx.com.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com


Advertisement